BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 10590778)

  • 1. [Opportunistic screening for genital infections with Chlamydia trachomatis among the sexually active population in Amsterdam. III. Cost-effectiveness analysis of screening women and the role of reinfection and partner treatment].
    Postma MJ; Welte R; van den Hoek JA; Jager JC; van Doornum GJ; Coutinho RA
    Ned Tijdschr Geneeskd; 1999 Nov; 143(47):2383-5. PubMed ID: 10590778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Opportunistic screening for genital infections with Chlamydia trachomatis in sexually active population of Amsterdam. II. Cost-effectiveness analysis of screening women].
    Postma MJ; Welte R; van den Hoek JA; van Doornum GJ; Coutinho RA; Jager JC
    Ned Tijdschr Geneeskd; 1999 Mar; 143(13):677-81. PubMed ID: 10321301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Opportunistic screening for genital infections with Chlamydia trachomatis in sexually active population of Amsterdam. II. Cost-effectiveness analysis of screening women].
    Ruitenberg EN
    Ned Tijdschr Geneeskd; 1999 May; 143(19):1012. PubMed ID: 10368724
    [No Abstract]   [Full Text] [Related]  

  • 4. [Opportunistic screening for genital infections with Chlamydia trachomatis among the sexually active population of Amsterdam. Il Over 90% participation and almost 5% prevalence].
    van den Hoek JA; Mulder-Folkerts DK; Coutinho RA; Dukers NH; Buimer M; van Doornum GJ
    Ned Tijdschr Geneeskd; 1999 Mar; 143(13):668-72. PubMed ID: 10321299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of partner pharmacotherapy in screening women for asymptomatic infection with Chlamydia Trachomatis.
    Postma MJ; Welte R; van den Hoek JA; van Doornum GJ; Jager HC; Coutinho RA
    Value Health; 2001; 4(3):266-75. PubMed ID: 11705188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Screening for asymptomatic Chlamydia trachomatis infection in pregnancy; cost-effectiveness favorable at a minimum prevalence rate of 3% or more].
    Postma MJ; Bakker A; Welte R; van Bergen JE; van den Hoek JA; de Jong-van den Berg LT; Jager JC
    Ned Tijdschr Geneeskd; 2000 Dec; 144(49):2350-4. PubMed ID: 11129971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Screening for Chlamydia trachomatis infection: which group should be targeted and at what price?].
    van Vloten WA
    Ned Tijdschr Geneeskd; 1999 Mar; 143(13):652-3. PubMed ID: 10321294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The program cost and cost-effectiveness of screening men for Chlamydia to prevent pelvic inflammatory disease in women.
    Gift TL; Gaydos CA; Kent CK; Marrazzo JM; Rietmeijer CA; Schillinger JA; Dunne EF
    Sex Transm Dis; 2008 Nov; 35(11 Suppl):S66-75. PubMed ID: 18830137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of screening adolescent males for Chlamydia on admission to detention.
    Blake DR; Gaydos CA; Quinn TC
    Sex Transm Dis; 2004 Feb; 31(2):85-95. PubMed ID: 14743071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An evaluation of economics and acceptability of screening for Chlamydia trachomatis infection, in women attending antenatal, abortion, colposcopy and family planning clinics in Scotland, UK.
    Norman JE; Wu O; Twaddle S; Macmillan S; McMillan L; Templeton A; McKenzie H; Noone A; Allardice G; Reid M
    BJOG; 2004 Nov; 111(11):1261-8. PubMed ID: 15521872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Managing genital chlamydia trachomatis infection in Scotland: targeted opportunistic testing or a screening programme?
    Clutterbuck DJ
    Health Bull (Edinb); 2001 Nov; 59(6):396-404. PubMed ID: 12661390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost and cost-effectiveness of opportunistic screening for Chlamydia trachomatis in Ireland.
    Gillespie P; O'Neill C; Adams E; Turner K; O'Donovan D; Brugha R; Vaughan D; O'Connell E; Cormican M; Balfe M; Coleman C; Fitzgerald M; Fleming C
    Sex Transm Infect; 2012 Apr; 88(3):222-8. PubMed ID: 22213681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Universal screening or prophylactic treatment for Chlamydia trachomatis infection among women seeking induced abortions: which strategy is more cost-effective?
    Chen S; Li J; van den Hoek A
    Sex Transm Dis; 2007 Apr; 34(4):230-6. PubMed ID: 17414068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic screening for Chlamydia trachomatis: estimating cost-effectiveness using dynamic modeling and Dutch data.
    de Vries R; van Bergen JE; de Jong-van den Berg LT; Postma MJ;
    Value Health; 2006; 9(1):1-11. PubMed ID: 16441519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Screening for asymptomatic Chlamydia trachomatis infection: cost-effectiveness favorable at a minimum prevalence rate of 3% or more].
    Habets PC
    Ned Tijdschr Geneeskd; 2001 Mar; 145(10):499-501. PubMed ID: 11268916
    [No Abstract]   [Full Text] [Related]  

  • 16. A prediction rule for selective screening of Chlamydia trachomatis infection.
    Götz HM; van Bergen JE; Veldhuijzen IK; Broer J; Hoebe CJ; Steyerberg EW; Coenen AJ; de Groot F; Verhooren MJ; van Schaik DT; Richardus JH
    Sex Transm Infect; 2005 Feb; 81(1):24-30. PubMed ID: 15681717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cost-effectiveness evaluation of a jail-based chlamydia screening program for men and its impact on their partners in the community.
    Gift TL; Lincoln T; Tuthill R; Whelan M; Briggs LP; Conklin T; Irwin KL
    Sex Transm Dis; 2006 Oct; 33(10 Suppl):S103-10. PubMed ID: 17003677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Potentials of screening for Chlamydia trachomatis in Hungary: cost-benefit analysis].
    Nyári T; Mészáros G; Deák J; Nagy E; Kovács L
    Orv Hetil; 2000 Jul; 141(27):1511-6. PubMed ID: 10943109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimation of the burden of disease and costs of genital Chlamydia trachomatis infection in Canada.
    Tuite AR; Jayaraman GC; Allen VG; Fisman DN
    Sex Transm Dis; 2012 Apr; 39(4):260-7. PubMed ID: 22421691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overestimation of complication rates in evaluations of Chlamydia trachomatis screening programmes--implications for cost-effectiveness analyses.
    van Valkengoed IG; Morré SA; van den Brule AJ; Meijer CJ; Bouter LM; Boeke AJ
    Int J Epidemiol; 2004 Apr; 33(2):416-25. PubMed ID: 15082651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.